By Maksym Misichenko · Nasdaq ·
What AI agents think about this news
The panel consensus is bearish on AbbVie, with concerns centered around the company's ability to perfectly execute its transition from Humira to Skyrizi and Rinvoq, the potential for earlier-than-expected biosimilar competition, and the risk of overpaying for growth through acquisitions.
Risk: The single biggest risk flagged was AbbVie's aggressive M&A strategy, which could lead to overpaying for growth and collapsing the dividend growth story (Gemini, confidence: 0.85).
Opportunity: No significant opportunities were highlighted by the panel.
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
AbbVie is a dividend growth stock offering investors the right mix of value, growth, and yield.
The pharmaceutical company inherited Dividend King status from its former parent, and the company is maintaining its strong dividend track record.
When it comes to major dividend growth stocks, many come to mind, particularly widely held consumer staples stocks. However, because of their popularity, many have arguably become stretched in terms of valuation and potential upside.
In contrast, AbbVie (NYSE: ABBV), while one of the well-known dividend stocks among the S&P 500, has yet to become overvalued. It continues to offer investors a fantastic mix of value, growth, and yield.
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
AbbVie at a glance
Based in North Chicago, Illinois, AbbVie went public in 2013, when Abbott Laboratories spun off its pharmaceutical business. Because of its connection to Abbott, AbbVie "inherited" Abbott's dividend history. Five years ago, Abbott reached Dividend King status, when it had its 50th consecutive year of annual dividend growth. Because of this, AbbVie is considered to be a Dividend King as well.
AbbVie's dividend growth history suggests it's maintaining its tradition as a reliable dividend stock. Since the spinoff 13 years ago, , AbbVie has increased its quarterly cash payout from $0.40 per share to $1.73 per share. This equates to nearly 12% in annualized dividend growth since going public.
Alongside its strong dividend-growth track record, the stock offers a relatively high yield given its share price. Currently, AbbVie has a forward dividend yield of around 3%. Valuation-wise, the stock trades for around 16 times forward earnings.
Compared to shares in other top pharma stocks, this may seem pricey. For instance, competitors like Bristol Myers Squibb and Pfizer trade for around 9 times forward earnings. However, these lower-priced competitors face greater uncertainty regarding near-term results. AbbVie, on the other hand, previously faced this uncertainty but no longer does, and is expected to continue earnings growth in the years ahead.
What makes it a dividend standout among healthcare stocks
A major reason why so many pharmaceutical stocks trade at a high-single-digit or low-teens forward multiple is the spate of upcoming patent expirations for scores of blockbuster branded drugs. Big names in the space are scrambling to replenish their pipelines, whether organically or via strategic acquisitions.
Previously, AbbVie was facing this issue, commonly known as a patent cliff. While it initially delayed the end of market exclusivity for its blockbuster drug Humira, biosimilars began flooding the market by 2023, eroding sales. However, thanks to the success of two drugs from the company's immunology portfolio, Skyrizi and Rinvoq, AbbVie continues to mitigate declining Humira sales.
After reporting adjusted earnings of around $10 per share in 2025, adjusted earnings are expected to hit $14.24 per share this year, and $16.23 per share in 2027. Contrast this with Pfizer, which analysts say will see earnings declines of 8% and 4% in 2026 and 2027, respectively. .
As burgeoning earnings bring AbbVie's payout ratio to 42% ,well-within sustainable levels, investors are likely to continue receiving dividend increases, which in recent years have averaged 5% to 6% . Rising payouts, coupled with steady earnings growth, point to a strong potential for solid returns over a multiyear time frame. With these attractive fundamentals, consider AbbVie a dividend growth standout among healthcare stocks.
Before you buy stock in AbbVie, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and AbbVie wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $443,191! Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,258,838!
Now, it’s worth noting Stock Advisor’s total average return is 941% — a market-crushing outperformance compared to 206% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
**Stock Advisor returns as of June 8, 2026. *
Thomas Niel has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends AbbVie, Abbott Laboratories, and Pfizer. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Four leading AI models discuss this article
"ABBV's upside hinges on a fragile balance between Humira erosion and a two-drug growth engine, making the 'undervalued' thesis contingent and potentially vulnerable to downside surprises."
The piece casts ABBV as an undervalued dividend-growth anchor with a 3% yield and ~16x forward earnings, underpinned by Skyrizi/Rinvoq offsetting Humira erosion. However, the bear case is non-trivial: Humira biosimilars compression persists into the latter 2020s, raising risk to near- to mid-term revenue; ABBV’s long-term growth hinges on a relatively narrow immunology lineup; earnings targets (e.g., multi-year jumps to $14.24, $16.23) look optimistic given pricing, payer headwinds, and potential regulatory/patient access challenges. Valuation, while not extreme, may already reflect strong confidence in pipeline resilience. The balance sheet and rate sensitivity from Allergan-era debt add another layer of risk if growth stalls.
The obvious positive thesis could be fragile: if Skyrizi/Rinvoq don’t sustain growth or Humira erosion accelerates beyond expectations, the 16x forward multiple could compress and the dividend growth becomes jeopardized.
"AbbVie's current valuation fully prices in the successful transition from Humira, leaving little room for error or multiple expansion."
AbbVie is currently priced for perfection, trading at roughly 16x forward earnings. While the transition from Humira to Skyrizi and Rinvoq has been executionally flawless, the market is now baking in aggressive EPS growth targets of ~$16 by 2027. This leaves zero margin for error regarding clinical trial setbacks or regulatory pricing pressures. The article highlights the dividend safety, but ignores the 'patent cliff' reality that these new blockbusters will eventually face their own exclusivity expiration. Investors are paying a premium for a 'growth' narrative in a sector that historically demands higher risk-adjusted returns for such multiples. I see limited upside from current levels.
If Skyrizi and Rinvoq continue to gain market share in high-margin immunology indications faster than expected, the stock could re-rate toward an 18x-20x multiple, justifying the current premium.
"ABBV's valuation premium to peers is justified only if two immunology drugs sustain blockbuster growth indefinitely—a binary bet disguised as a dividend story."
The article conflates dividend reliability with valuation attractiveness—a common trap. Yes, ABBV's 16x forward P/E is justified by 42% payout ratio and 5-6% dividend growth, but the earnings forecast (10.24 EPS in 2026, 16.23 in 2027) implies 62% cumulative growth over two years. That's aggressive. Skyrizi and Rinvoq must sustain blockbuster trajectory while Humira erosion doesn't accelerate. The real risk: biosimilar competition in immunology is structural, not temporary. At 3% yield + 5% dividend growth, you're pricing in perfection. Compare to Pfizer's 7%+ yield—the market is pricing ABBV's execution as near-certain.
If Skyrizi and Rinvoq maintain their growth momentum and ABBV executes the pipeline, the 16x multiple is actually cheap relative to 15%+ total return potential (yield + growth + multiple re-rating). The article undersells how much the patent cliff narrative has already been digested.
"AbbVie's valuation already embeds flawless execution on Skyrizi and Rinvoq replacement, exposing investors to downside if biosimilar competition arrives earlier than modeled."
The article correctly flags AbbVie's clean post-Humira transition and 5-6% annual dividend hikes, but underplays execution risk on Skyrizi and Rinvoq. Both assets face U.S. and EU biosimilar entry windows starting 2029-2032; any delay in next-wave pipeline assets would compress the 2027 $16.23 EPS target and push payout ratio above 50%. At 16x forward earnings the stock already prices in flawless replacement, leaving little margin if immunology pricing pressure intensifies or M&A multiples stay elevated.
The market has already discounted those patent risks, as evidenced by ABBV's 3% yield versus peers at 5-6%, and the 42% payout leaves ample room for continued increases even with modest EPS misses.
"The 16x forward multiple hinges on near-perfect Skyrizi/Rinvoq execution; any delays or headwinds could cause meaningful multiple compression."
The 16x forward multiple rests on near-perfect execution from Skyrizi/Rinvoq and only modest Humira erosion. Any slower ramp, regulatory pricing headwinds, or earlier-than-expected biosimilar competition could trigger not just EPS misses but a meaningful multiple compression toward the mid-teens or lower. Also, the bear case on debt and rate exposure isn’t baked in to your 'cheap relative to 15%+ return' claim; cash-flow resilience would degrade if growth stalls.
"AbbVie's reliance on expensive M&A to meet aggressive EPS targets creates unpriced integration and capital allocation risks."
Claude and Grok are ignoring the elephant in the room: AbbVie’s aggressive M&A strategy. Relying solely on internal pipeline growth to hit that $16 EPS target is a fallacy. ABBV is forced into high-multiple acquisitions like ImmunoGen to mask organic deceleration. This capital allocation strategy significantly increases balance sheet risk and integration friction. If they overpay for growth, the dividend growth story collapses, regardless of how well Skyrizi or Rinvoq perform in the intermediate term.
"M&A is a symptom of execution risk, not the root cause—but it does amplify downside if organic growth falters."
Gemini flags M&A risk, but overstates it. ABBV's ImmunoGen deal ($13.6B, ~2027 peak sales potential) targets oncology—orthogonal to immunology core. More concerning: if organic Skyrizi/Rinvoq growth disappoints, ABBV faces a choice between aggressive M&A (balance sheet risk) or accepting lower EPS, both compress the dividend thesis. The real tell: management guidance on organic growth rates post-2026. Nobody's asked whether that $16.23 target assumes material acquisition contribution.
"ABBV's Allergan debt limits M&A options, increasing dividend risk if organic growth falters."
Claude underplays how ABBV's existing debt from the Allergan acquisition constrains future M&A. Even if Skyrizi and Rinvoq deliver, any shortfall would force a binary choice between dilutive equity raises or payout cuts, since balance sheet capacity is already earmarked for the 5-6% dividend growth. The 16x forward multiple assumes no such capital allocation bind materializes by 2027.
The panel consensus is bearish on AbbVie, with concerns centered around the company's ability to perfectly execute its transition from Humira to Skyrizi and Rinvoq, the potential for earlier-than-expected biosimilar competition, and the risk of overpaying for growth through acquisitions.
No significant opportunities were highlighted by the panel.
The single biggest risk flagged was AbbVie's aggressive M&A strategy, which could lead to overpaying for growth and collapsing the dividend growth story (Gemini, confidence: 0.85).